Ono Pharmaceutical's first quarter of the fiscal year ending March 2027 saw revenue fall 8.9% year on year to 116.1 billion yen, while operating profit rose 39.4% to 30.6 billion yen and net profit climbed 36.7% to 24.1 billion yen. According to the company, among the costs excluded from core results, amortization of intangible assets came to 6 billion yen and the expensing of inventory measured at fair value came to 2 billion yen, both below year-earlier levels and helping to support the profit gain. However, the combined decline in these two items fell short of 1 billion yen, suggesting that broader cost reductions, including in cost of sales and research and development expenses, were the main driver. For the full year, the company plans revenue of 455 billion yen, down 11.8% from the previous year, while targeting operating profit of 94 billion yen, up 1.9%, and net profit of 71 billion yen, up 1.8%, a plan that anticipates a larger revenue decline than in the first quarter while keeping profit roughly in line with the prior year. At the first-quarter stage, progress against the full-year plan stands at 25.5% for revenue, roughly the one-quarter mark, while operating profit is somewhat ahead at 32.6%. For the full fiscal year ended March 2026, revenue was 515.7 billion yen, up 5.9%, operating profit was 92.2 billion yen, up 54.4%, and net profit was 69.7 billion yen, up 39.4%, though that period included a rebound effect from the prior year's cost of sales, which had included a 13.6 billion yen sales milestone for Forxiga tablets under a co-promotion agreement with AstraZeneca.
ONO Pharmaceutical Co., Ltd.Ono's Q1 operating profit jumped 39.4% to 30.6 billion yen on broader cost reductions, with full-year profit guidance roughly in line despite lower revenue.
AstraZeneca PLC